ストックスクリーナーアプリを入手
26.51
4.54%
-1.47
前日終値:
$27.98
開ける：
$28
24時間の取引高:
817.24K
Relative Volume:
0.19
時価総額：
$3.29B
収益：
-
当期純損益:
$-99.15M
株価収益率:
-28.51
EPS:
-0.93
ネットキャッシュフロー:
$-74.25M
1週間 パフォーマンス:
-11.17%
1か月 パフォーマンス:
-3.99%
6か月 パフォーマンス:
-57.14%
1年 パフォーマンス:
-66.96%
1日の値動き範囲:
$26.55
$28.19
1週間の範囲:
$26.73
$30.75
52週間の値動き範囲:
$24.44
$85.20
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
26.57 | 3.29B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.52 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.90 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
588.05 | 35.74B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.70 | 35.58B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.85 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - StockTitan
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly - MSN
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know - Yahoo Finance
(VKTX) Investment Analysis - Stock Traders Daily
Market Whales and Their Recent Bets on VKTX Options - Benzinga
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street - Yahoo Finance
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? - Nasdaq
Why Novo Nordisk Stock Outpaced the Market on Tuesday - The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? - MarketBeat
Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - MSN
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. - MSN
Health Care Down as Traders Seek Out Defensive Sectors -- Health Care Roundup -March 14, 2025 at 05:24 pm EDT - Marketscreener.com
Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - MSN
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - MSN
Viking Therapeutics: No Buyout Needed Now (NASDAQ:VKTX) - Seeking Alpha
(VKTX) Long Term Investment Analysis - Stock Traders Daily
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma - Zacks Investment Research
Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World
10 Stocks Skyrocketing Today - Insider Monkey
Why VKTX Stock is Moving Today - GuruFocus.com
Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal - TipRanks
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo
Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in. - MarketWatch
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking shares slip after manufacturing deal announced - The Pharma Letter
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply - Yahoo Finance
Viking Therapeutics Is Ready For A Standalone Future (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating - TipRanks
Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects - TipRanks
Bank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations - Barchart
Health Care Down on Flight From Biotech, Obesity Drug Makers -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 - The Malaysian Reserve
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade) - Seeking Alpha
Stellantis, Tesla, Viking Therapeutics: Market Minute - Yahoo Finance
Viking Therapeutics closer to bringing its Ozempic competitor to market - Yahoo Finance
Viking Therapeutics Shares Fall After Manufacturing Deal With CordenPharma -March 11, 2025 at 11:08 am EDT - Marketscreener.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Strategic Manufacturing Deal Boosts Viking Therapeutics’ Stock Outlook - TipRanks
Viking Therapeutics Signs Broad Manufacturing Agreement with CordenPharma - Contract Pharma
Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications - Marketscreener.com
Viking Therapeutics inks production deal for obesity drug - MSN
Viking Therapeutics stock in focus after CDMO deal (VKTX) - Seeking Alpha
H.C. Wainwright maintains Buy on Viking Therapeutics stock By Investing.com - Investing.com UK
Viking Therapeutics Signs Manufacturing Deal With CordenPharma for Obesity Program - Marketscreener.com
Viking Therapeutics signs broad manufacturing agreement with CordenPharma - TipRanks
VKTXViking Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Viking Therapeutics secures supply for obesity drug - Investing.com India
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
Viking Therapeutics Inc (VKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mancini Marianna | Chief Operating Officer |
Jan 06 '25 |
Sale |
42.75 |
54,215 |
2,317,599 |
374,134 |
| ZANTE GREG | Chief Financial Officer |
Jan 06 '25 |
Sale |
42.75 |
50,309 |
2,150,595 |
165,259 |
1.66%
4.32%
大文字化:
|
ボリューム (24 時間):